UNASSIGNED: The study was conducted by descriptive method with longitudinal follow-up on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam, from July 2013 to December 2016.
UNASSIGNED: Univariate analysis showed that there was a relationship between the recurrence characteristics in the studied patients and the characteristics of lymph node metastasis (P = 0.026; OR = 15; 95% CI = 1.4-163.2) and BRAF V600E mutation status (P = 0.01; OR = 3.41; 95% CI = 1.31-8.88). When analysing the multivariable Logistic regression model, there was a positive correlation between the occurrence of BRAF V600E gene mutation (P = 0.032; OR = 17.649; 95% CI = 1.290-241.523) and male sex (P = 0.036; OR = 12.788; 95% CI = 1.185-137.961) and the occurrence of recurrence in study patients. The mean time to relapse was earlier in male patients than in female patients (P = 0.02). The mean time to relapse in patients with the BRAF V600E mutation (31.81 ± 1.14 months) was shorter than the mean time to relapse in the group without the mutation (57.82 ± 2.08 months) (P = 0.01). The group of patients with mutations in the BRAF V600E gene increased the risk of recurrence compared with the group without the mutation (HR = 9.14, P = 0.04).
UNASSIGNED: There is a positive correlation between recurrence and masculinity, lymph node metastasis and the occurrence of BRAF V600E mutations in thyroid carcinoma patients.
■本研究采用描述性方法对103军医院102例甲状腺癌患者进行纵向随访,河内,越南,从2013年7月到2016年12月。
■单因素分析表明,患者的复发特征与淋巴结转移特征(P=0.026;OR=15;95%CI=1.4-163.2)和BRAFV600E突变状态(P=0.01;OR=3.41;95%CI=1.31-8.88)之间存在相关性。在分析多变量Logistic回归模型时,BRAFV600E基因突变(P=0.032;OR=17.649;95%CI=1.290~241.523)和男性(P=0.036;OR=12.788;95%CI=1.185~137.961)的发生与研究患者复发的发生呈正相关。男性患者的平均复发时间早于女性患者(P=0.02)。BRAFV600E突变组的平均复发时间(31.81±1.14个月)短于无突变组的平均复发时间(57.82±2.08个月)(P=0.01)。BRAFV600E基因突变组的复发风险高于无突变组(HR=9.14,P=0.04)。
■复发与男子气概呈正相关,甲状腺癌患者的淋巴结转移和BRAFV600E突变的发生。